Anti-tumor immune therapy with programmed death-1 and its ligand inhibitors: Research advances
10.13220/j.cnki.jipr.2016.05.002
- Author:
Fen LAN
1
Author Information
1. Department of Pharmacy, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Anti-tumor therapy;
Immune therapy;
Inhibitors;
Ligand;
Programmed death-1
- From:
Journal of International Pharmaceutical Research
2016;43(5):813-817
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors are a novel kind of immune checkpoint blockers, which are the highlights of anti-tumor immune therapy. PD-1 inhibitors, such as nivolumab and pembrolizumab have been granted by the market authorization to treat melanoma and non-small cell lung cancer. Clinical trials of their efficacy and safety on renal cell carcinoma, bladder carcinoma and Hodgkin′s lymphoma are still in process. PD-L1 inhibitors atezolizumab, durvalumab and avelumab have been approved by FDA for treatment of urothelial carcinoma. Several other drugs are in phase I clinical trials. This paper gives a brief summary of recent advances in the studies on PD-1/PD-L1 inhibitors.
